Endo Health downgraded to Underperform from Sector Perform at RBC Capital RBC Capital downgraded Endo Health given valuation and concerns regarding the future of the Opana ER franchise due to potential future generics. Price target lowered to $24 from $25.
Endo upgraded to Overweight from Neutral at Piper Jaffray Piper Jaffray upgraded Endo (ENDP) to Overweight with an $84 price target citing an improved asset base following the takeover of Auxilium (AUXL).
Auxilium downgraded to Neutral from Buy at Mizuho Mizuho downgraded Auxilium (AUXL) to Neutral following the company's agreement to be acquired by Endo (ENDP). The firm expects shareholders to approve the deal and does not expect a competing bid.